Oncolytics Biotech, Inc.
ONCYOncolytics Biotech is a clinical-stage biopharmaceutical company focused on the development of pelareorep, a proprietary intravenously delivered immunotherapeutic agent.
Table of contents
Earnings
Next report
Aug 14, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
By net margin
Profile
Oncolytics Biotech is a clinical-stage biopharmaceutical company focused on the development of pelareorep, a proprietary intravenously delivered immunotherapeutic agent. The company's core value proposition lies in using a non-pathogenic reovirus to selectively replicate in RAS-mutated tumors, activating the immune system to make cancers more susceptible to existing treatments like chemotherapy and checkpoint inhibitors.
A clinical-stage developer of a niche viral immunotherapy platform targeting the tumor microenvironment to enhance the efficacy of standard-of-care oncology treatments.
Questions, answered.
- What is Oncolytics Biotech, Inc.'s market cap?
- Oncolytics Biotech, Inc. (ONCY) has a market capitalization of $95.5M and trades on NASDAQ.
- Who are Oncolytics Biotech, Inc.'s competitors?
- Oncolytics Biotech, Inc.'s key competitors include Replimune Group, Amgen, CG Oncology, and others. These companies compete in similar markets and product categories.
- Who does Oncolytics Biotech, Inc. partner with?
- Oncolytics Biotech, Inc.'s notable partners include Merck & Co., Bristol-Myers Squibb, Roche Holding AG.
- Where is Oncolytics Biotech, Inc. headquartered?
- Oncolytics Biotech, Inc. is headquartered in Canada and employs approximately 27 people. It has been publicly traded since 2001.